Immutep Announces Successful Completion of FDA Project Optimus Requirements
MWN-AI** Summary
Immutep Limited has announced the successful completion of FDA Project Optimus requirements, confirming a 30mg dose of its investigational immunotherapy, eftilagimod alfa (efti), as the optimal biological dose for its oncology pipeline. This positive outcome marks a pivotal moment for Immutep as it progresses toward future Biological License Applications (BLA). The announcement, made on October 13, 2025, indicates that the company is now moving forward with its TACTI-004 (KEYNOTE-F91) Phase III trial, which assesses efti in conjunction with Merck’s KEYTRUDA (pembrolizumab) and chemotherapy for treating advanced non-small cell lung cancer (NSCLC).
Immutep's Chief Development Officer, Christian Mueller, expressed gratitude for the FDA's supportive feedback and emphasized the importance of establishing the optimal dose of efti. This consensus significantly de-risks the clinical development pathway for efti and strengthens its position in the oncology market. Efti, classified as a first-in-class immunotherapy, works by activating antigen-presenting cells, initiating an expansive anti-cancer immune response that includes activating cytotoxic T cells.
The TACTI-004 trial is crucial as it evaluates the efficacy of efti as a frontline treatment for NSCLC irrespective of PD-L1 expression, aiming to enhance therapeutic outcomes for patients. With the regulatory clarity achieved, clinical site openings in the U.S. are in progress, setting the stage for pivotal data that could inform future treatment paradigms.
Immutep continues to be recognized for its innovative work in immunotherapies related to LAG-3, with efti also under evaluation for other tumors such as head and neck cancer and breast cancer. The company aims to deliver new treatment options to patients while maximizing shareholder value. Further information is available on Immutep's website.
MWN-AI** Analysis
Immutep Limited’s recent announcement regarding the successful completion of FDA Project Optimus requirements and the agreement on a 30mg optimal biological dose for eftilagimod alfa (efti) is a pivotal milestone for the company. This de-risking event enhances the credibility of Immutep’s ongoing and future clinical trials, particularly the TACTI-004 (KEYNOTE-F91) Phase III trial, which is now progressing to site openings in the United States.
Investors should view this development positively, as it bolsters the pipeline for shares of IMMP. The FDA’s endorsement of efti’s dosing strategy positions Immutep favorably against competitors, enhancing its attractiveness to potential partners and investors. As the trial evaluates efti combined with KEYTRUDA® and chemotherapy for first-line non-small cell lung cancer (NSCLC), a recognized medical need exists in a market poised for substantial growth. The positive reception from the FDA also signals a heightened likelihood of successful registration, which could lead to the company filing its Biologics License Application (BLA) in the near future and potentially accessing significant market revenues.
Moreover, investors should consider Immutep's diversified portfolio and its strategic position within the immunotherapy sector. The focus on various solid tumors, including those with a favorable safety profile for combination therapies, indicates robust potential for market entry across multiple indications. Given the increasing pressure to innovate in cancer treatment and the promising efficacy of combination therapies, Immutep holds a key competitive edge.
In light of these factors, prospective and current investors may benefit from closely monitoring Immutep’s trial developments and FDA interactions. Analysts should consider initiating or maintaining positions in IMMP, as successful trial outcomes and subsequent FDA approvals could yield considerable returns.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Confirmation of 30mg efti as optimal biological dose relevant for Immutep’s oncology pipeline and potential future Biological License Applications (BLA)
- Registrational TACTI-004 (KEYNOTE-F91) Phase III trial in first line non-small cell lung cancer now in process of opening clinical sites in the United States
SYDNEY, AUSTRALIA, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that positive and straightforward feedback has been received from the US Food and Drug Administration (“FDA”) regarding the successful completion of Project Optimus requirements and agreement on 30mg as the optimal biological dose for eftilagimod alfa (efti).
Immutep’s Chief Development Officer, Christian Mueller , said, “We are very thankful for the FDA’s positive feedback and productive discussions over the past few years. The alignment on efti’s optimal biologic dose has strategic relevance to our efti oncology programs and is a major de-risking event and building block towards future BLA filings. We are excited to successfully conclude this chapter of efti’s clinical development and are intently focused on bringing this novel immunotherapy to market to help address the needs of cancer patients worldwide.”
The agreement with the FDA on efti’s optimal biological dosing carries strategic importance in the ongoing and future clinical development of this first-in-class immunotherapy, including the global TACTI-004 (KEYNOTE-F91) Phase III trial evaluating efti in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA ® (pembrolizumab), and chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer (1L NSCLC), regardless of PD-L1 expression. With the conclusion of Project Optimus , this registrational study is now in process of opening sites in the United States.
About Eftilagimod Alfa (Efti)
Efti is a novel immunotherapy that directly activates antigen-presenting cells or APCs (e.g. dendritic cells, monocytes) via the MHC Class II pathway to fight cancer. As an MHC Class II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important co-stimulatory signals & cytokines that further boost the immune system’s ability to combat cancer.
Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC) in a pivotal Phase III trial called TACTI-004 (KEYNOTE-F91), as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable safety profile enables various combinations like with anti-PD-[L]1 immunotherapy, radiotherapy, and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease . The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com .
KEYTRUDA ® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
U.S. Investors/Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
FAQ**
How does the confirmation of 30mg efti as the optimal biological dose impact Immutep Limited IMMP’s strategy for the ongoing TACTI-004 trial and potential BLA submissions?
What specific safety and efficacy data from the TACTI-004 trial could support Immutep Limited IMMP's future BLA applications following the FDA’s agreement on efti’s dosing?
In what ways does the FDA’s feedback on efti bolster confidence in Immutep Limited IMMP’s oncology pipeline, particularly regarding future partnerships and investments?
How might the positive FDA feedback shape the timeline and clinical development pathway for Immutep Limited IMMP’s other indications such as HNSCC and soft tissue sarcoma?
**MWN-AI FAQ is based on asking OpenAI questions about Immutep Limited (NASDAQ: IMMP).
NASDAQ: IMMP
IMMP Trading
-14.22% G/L:
$0.4556 Last:
5,373,194 Volume:
$0.49 Open:
